Icu Medical Inc.
and Overview of Business ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide.
$162.99
-$4.24 (-2.54%)
EOD Oct 16, 2026
Operating margin is thin at 4.90%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 6.3% YoY. The question is whether this is cyclical or a structural shift.
At 137x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 26% versus the prior year, cash generation momentum has weakened.
137.0x earnings, 26.7x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.16B
▼ -6.3% YoY
Net Income (TTM)
$30M
▲ +100.6% YoY
Op. Margin
6.42%
▲ +3.1pp YoY
ROIC
3.16%
▲ +2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$153M
▼ -26.4% YoY
Op. Cash Flow (TTM)
$236M
▼ -11.9% YoY
Net Debt
$989M
Cash & Equiv.
$298M
5Y CAGR: +11.9%
5Y CAGR: -6.8%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Icu Medical (ICUI) overvalued?
At a P/E of 137.0 and a price-to-free-cash-flow of 26.7, Icu Medical (ICUI) trades above a two-stage DCF intrinsic value of about $66.27 per share, so at $162.99 the stock looks overvalued (59.3% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Icu Medical scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Icu Medical's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $66.27 per share for ICUI, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $49.70. At today's $162.99, that puts the stock about 59.3% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Icu Medical a high-quality business?+
Icu Medical scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 6.4% operating margin and a 3.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Icu Medical a good stock to buy right now?+
That depends on valuation and quality together, not either alone. ICUI currently trades above its estimated intrinsic value and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.